Visceral Pain Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The visceral pain market size has grown strongly in recent years. It will grow from $13.84 billion in 2024 to $14.87 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to aging population, increased incidence of chronic diseases, advances in medical research, expansion of healthcare infrastructure, rising awareness and diagnosis rates.

The visceral pain market size is expected to see strong growth in the next few years. It will grow to $18.71 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to technological innovations in pain management, growing demand for non-invasive treatment options, emerging markets and untapped opportunities, personalized medicine approaches, integration of digital health solutions. Major trends in the forecast period include shift towards multimodal pain management, increasing emphasis on alternative therapies, rise of targeted therapies for specific pain types, growing role of telemedicine in pain management, integration of artificial intelligence in pain assessment.

The growing demand for analgesics is anticipated to drive the expansion of the visceral pain market in the future. Analgesics are medications that relieve pain by reducing or blocking the brain's perception of pain signals. These medications help manage visceral pain by acting on the nervous system to modulate pain signals from internal organs. For example, in April 2024, the New England Journal of Medicine, a UK-based weekly medical journal, reported that over 53,600 clinicians were prescribing buprenorphine by December 2023, marking an increase of 11,500 prescribers compared to December 2022. Thus, the rising demand for analgesics is fueling the growth of the visceral pain market.

Prominent companies in the visceral pain market are dedicated to developing innovative products such as NHE3 Inhibitors to offer dependable solutions to consumers. NHE3 inhibitors constitute a class of medications that function by inhibiting the Sodium-Proton-Exchanger subtype 3 (NHE3) in the gastrointestinal tract. For example, in April 2022, Ardelyx, a US-based biopharmaceutical firm, introduced an NHE3 Inhibitor medication called IBSRELA. This groundbreaking treatment targets adults with irritable bowel syndrome with constipation (IBS-C), acting on the Sodium-Hydrogen Exchanger 3 (NHE3) in the small intestine and colon. Preclinical studies have demonstrated its efficacy in reducing abdominal pain by alleviating visceral hypersensitivity and intestinal permeability.

In April 2023, Marksans Pharma, a pharmaceutical company based in India, acquired Teva Pharmaceuticals' manufacturing facility in India for an undisclosed amount. This acquisition provides Marksans with a 47,597-square-meter facility, allowing it to double its production capacity in India from 8 billion units per year. The increased capacity will facilitate the production of tablets, hard and soft gel capsules, ointments, liquids, and creams. Teva Pharmaceuticals is an Israel-based company that provides treatments for visceral pain.

Major companies operating in the visceral pain market report are Walgreens Boots Alliance Inc., Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co.Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Endo International PLC, Grünenthal GmbH, Glenmark Pharmaceuticals Limited, Hisamitsu Pharmaceutical Co. Ltd., Chromocell Corporation, Addex Therapeutics Ltd.

North America was the largest region in the visceral pain market in 2024. The regions covered in the visceral pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the visceral pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The visceral pain market consists of sales of opioids, anticonvulsants, gabapentin, and pregabalin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Visceral pain originates from internal organs such as the stomach, bladder, uterus, or rectum and can stem from factors such as inflammation, menstrual cramps, organ swelling, blockages, reduced blood flow, or tumors, particularly in the pelvis or abdomen, often accompanied by symptoms such as nausea, sweating, or increased heart rate.

The principal drug classes for treating visceral pain include calcium channel blockers (CCBs), nonsteroidal anti-inflammatories (NSAIDs), and others. CCBs regulate calcium ion movement into heart and blood vessel cells, with indications spanning interstitial cystitis, Crohn’s disease, irritable bowel syndrome, chronic prostatitis, and more. These medications are employed across various end-user settings including hospitals, homecare, specialty clinics, among others.

The visceral pain market research report is one of a series of new reports that provides visceral pain market statistics, including visceral pain industry global market size, regional shares, competitors with a visceral pain market share, detailed visceral pain market segments, market trends, and opportunities, and any further data you may need to thrive in the visceral pain industry. This visceral pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.